$CYCC
Cyclacel Pharmaceuticals, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024003713 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $29.00K $31.00K $420.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.582M $1.873M $6.718M
YoY Change -3.83% -12.6% -8.99%
% of Gross Profit
Research & Development $2.802M $3.518M $19.16M
YoY Change -50.62% -47.51% -5.52%
% of Gross Profit
Depreciation & Amortization $2.000K $8.000K $31.00K
YoY Change -75.0% 0.0% -3.13%
% of Gross Profit
Operating Expenses $4.384M $5.391M $25.87M
YoY Change -40.1% -39.05% -6.45%
Operating Profit -$4.355M -$25.45M
YoY Change -40.5% -7.97%
Interest Expense $3.000K -$333.0K -$148.0K
YoY Change -89.66% 109.43% -133.41%
% of Operating Profit
Other Income/Expense, Net $55.00K $0.00 -$98.00K
YoY Change -71.79% -100.0% -105.63%
Pretax Income -$4.300M -$5.693M -$25.55M
YoY Change -39.64% -36.74% -1.4%
Income Tax -$1.354M -$422.0K -$2.996M
% Of Pretax Income
Net Earnings -$2.946M -$5.321M -$22.56M
YoY Change -49.24% -28.76% 6.4%
Net Earnings / Revenue -10158.62% -17164.52% -5370.24%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.27 -$6.23 -$26.75
COMMON SHARES
Basic Shares Outstanding 1.318M 12.64M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.798M $3.378M $3.378M
YoY Change -75.53% -81.59% -81.59%
Cash & Equivalents $2.800M $3.378M $3.378M
Short-Term Investments
Other Short-Term Assets $365.0K $341.0K $4.066M
YoY Change -38.66% -19.95% 190.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.835M $7.444M $7.444M
YoY Change -74.52% -69.51% -69.51%
LONG-TERM ASSETS
Property, Plant & Equipment $7.000K $9.000K $102.0K
YoY Change -77.42% -71.88% -41.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.244M $1.259M $1.259M
YoY Change -57.34% -56.82% -56.82%
Total Long-Term Assets $1.330M $1.361M $1.361M
YoY Change -56.9% -55.95% -55.95%
TOTAL ASSETS
Total Short-Term Assets $4.835M $7.444M $7.444M
Total Long-Term Assets $1.330M $1.361M $1.361M
Total Assets $6.165M $8.805M $8.805M
YoY Change -72.05% -67.98% -67.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.200M $3.543M $3.543M
YoY Change 107.25% 38.34% 38.34%
Accrued Expenses $3.150M $4.618M $4.618M
YoY Change -34.77% -4.41% 17.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.350M $8.161M $8.161M
YoY Change 13.79% 10.4% 10.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $21.00K $37.00K $37.00K
YoY Change -73.75% -65.09% -65.09%
Total Long-Term Liabilities $21.00K $37.00K $37.00K
YoY Change -73.75% -65.09% -65.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.350M $8.161M $8.161M
Total Long-Term Liabilities $21.00K $37.00K $37.00K
Total Liabilities $8.371M $8.198M $8.198M
YoY Change 12.85% 9.34% 9.34%
SHAREHOLDERS EQUITY
Retained Earnings -$431.2M -$428.3M
YoY Change 4.68% 5.44%
Common Stock $1.000K $1.000K
YoY Change -88.89% -88.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.206M $607.0K $607.0K
YoY Change
Total Liabilities & Shareholders Equity $6.165M $8.805M $8.805M
YoY Change -72.05% -67.98% -67.98%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.946M -$5.321M -$22.56M
YoY Change -49.24% -28.76% 6.4%
Depreciation, Depletion And Amortization $2.000K $8.000K $31.00K
YoY Change -75.0% 0.0% -3.13%
Cash From Operating Activities -$483.0K -$3.910M -$16.11M
YoY Change -92.96% -24.36% -22.64%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $6.000K
YoY Change -100.0% -14.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$6.000K
YoY Change -100.0% -14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -79.00K 999.0K 848.0K
YoY Change 58.0% 2278.57% -71.71%
NET CHANGE
Cash From Operating Activities -483.0K -3.910M -16.11M
Cash From Investing Activities 0.000 0.000 -6.000K
Cash From Financing Activities -79.00K 999.0K 848.0K
Net Change In Cash -580.0K -2.911M -14.97M
YoY Change -91.61% -43.22% -17.83%
FREE CASH FLOW
Cash From Operating Activities -$483.0K -$3.910M -$16.11M
Capital Expenditures $0.00 $0.00 $6.000K
Free Cash Flow -$483.0K -$3.910M -$16.12M
YoY Change -92.97% -24.36% -22.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
628139
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1058892
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001130166
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22600000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
207807
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
00-50626
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
CY2023 dei City Area Code
CityAreaCode
908
CY2023 dei Local Phone Number
LocalPhoneNumber
517-7330
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5622362
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1318257
CY2023 dei Auditor Firm
AuditorFirmId
49
CY2023 dei Auditor Name
AuditorName
RSM US LLP
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3378000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7444000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
24411000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1259000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3465000
CY2023Q4 us-gaap Assets
Assets
8805000
CY2022Q4 us-gaap Assets
Assets
28050000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3543000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4618000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4950000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8161000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7511000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000
CY2023Q4 us-gaap Liabilities
Liabilities
8198000
CY2022Q4 us-gaap Liabilities
Liabilities
7617000
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
207807
CY2023Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
4494000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
303000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1058892
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
628139
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429796000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422981000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-908000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1316000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428282000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-405727000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
607000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15939000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8805000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28050000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
420000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
420000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19155000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20274000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6718000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7382000
CY2023 us-gaap Operating Expenses
OperatingExpenses
25873000
CY2022 us-gaap Operating Expenses
OperatingExpenses
27656000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-25453000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-27656000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-414000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
233000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
266000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
210000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1298000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-98000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1741000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25551000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25915000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2996000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4717000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22555000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2023 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22756000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21399000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-27.24
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22555000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-378000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12142000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20598000
CY2023 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
12550000
CY2022 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-21166000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22147000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21766000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37693000
CY2022 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
478000
CY2022 cycc Increase In Carrying Amount Of Redeemable Common Stock
IncreaseInCarryingAmountOfRedeemableCommonStock
1636000
CY2022 cycc Accretion On Redeemable Common Stock
AccretionOnRedeemableCommonStock
135000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1506000
CY2022 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
201000
CY2022 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-21166000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20598000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15939000
CY2023 cycc Issue Of Common Stock Preferred Stock Pre Funded Warrants And Warrants On Equity Financing Net Of Expenses
IssueOfCommonStockPreferredStockPreFundedWarrantsAndWarrantsOnEquityFinancingNetOfExpenses
1049000
CY2023 cycc Increase In Carrying Amount Of Redeemable Common Stock
IncreaseInCarryingAmountOfRedeemableCommonStock
-4494000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1473000
CY2023 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
201000
CY2023 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
12550000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12142000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22555000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
607000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22555000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2023 us-gaap Depreciation
Depreciation
31000
CY2022 us-gaap Depreciation
Depreciation
32000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1473000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1506000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-69000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
40000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4712000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3784000
CY2023 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
296000
CY2022 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
2577000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16112000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20827000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2023 cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
1049000
CY2022 cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
3199000
CY2023 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
201000
CY2022 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
201000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
848000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2998000
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
2400000
CY2023Q4 cycc Cash Financial Services Compensation Scheme Insured Amount
CashFinancialServicesCompensationSchemeInsuredAmount
85000
CY2023Q4 cycc Cash Exceeding Balance Insured By Financial Services Compensation Scheme
CashExceedingBalanceInsuredByFinancialServicesCompensationScheme
600000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14967000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18214000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3378000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2023 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
266000
CY2022 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
211000
CY2023 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
4846000
CY2022 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
3312000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2023 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2022 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2022 cycc Accretion On Redeemable Common Stock
AccretionOnRedeemableCommonStock
135000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21200000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428300000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000
CY2024Q1 us-gaap Cash
Cash
3400000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals and stock-based compensation expense. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company’s consolidated financial statements.</p>
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3378000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
2
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
420000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
75000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
4547000
CY2022 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2022Q4 cycc License Agreement Potential Future Milestone Payments
LicenseAgreementPotentialFutureMilestonePayments
0
CY2023Q4 cycc License Agreement Potential Future Milestone Payments
LicenseAgreementPotentialFutureMilestonePayments
0
CY2023Q4 us-gaap Cash
Cash
3303000
CY2022Q4 us-gaap Cash
Cash
13798000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2023Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
2933000
CY2022Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
4664000
CY2023Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
792000
CY2022Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
976000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
341000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
426000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2023Q4 cycc Deposits Held By Related Party
DepositsHeldByRelatedParty
1300000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
429000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
415000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
420000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
383000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2023Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3668000
CY2022Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3611000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
570000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
380000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1006000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4618000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4950000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
0
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
680000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
74218
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
62528
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
38000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
93000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1473000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1506000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1000000.0
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M10D
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-806000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1981000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-24745000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-23934000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25551000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25915000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-2998000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-4719000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-2996000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-4717000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2996000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4717000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
3000000.0
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
4700000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25551000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25915000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5366000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5442000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-5409000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4719000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
4865000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
6169000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1261000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2310000
CY2023 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
809000
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-3487000
CY2023 cycc Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
782000
CY2022 cycc Income Tax Reconciliation Nondeductible Expense And Tax Exempt Income
IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome
369000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
62000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
105000
CY2022 cycc Income Tax Reconciliation Foreign Income Tax Rate Differential And Repatriation Of Foreign Earnings
IncomeTaxReconciliationForeignIncomeTaxRateDifferentialAndRepatriationOfForeignEarnings
-20000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-2000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2996000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4717000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
57074000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
53092000
CY2023Q4 cycc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Depreciation Amortization And Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
39000
CY2022Q4 cycc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Depreciation Amortization And Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses
61000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
210000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
153000
CY2023Q4 cycc Deferred Tax Assets Lease Right Of Use Asset
DeferredTaxAssetsLeaseRightOfUseAsset
-26000
CY2022Q4 cycc Deferred Tax Assets Lease Right Of Use Asset
DeferredTaxAssetsLeaseRightOfUseAsset
-40000
CY2024Q1 us-gaap Preferred Stock Dividends Per Share Declared
PreferredStockDividendsPerShareDeclared
0.15
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 cycc Deferred Tax Assets Lease Right Of Use Liability
DeferredTaxAssetsLeaseRightOfUseLiability
26000
CY2022Q4 cycc Deferred Tax Assets Lease Right Of Use Liability
DeferredTaxAssetsLeaseRightOfUseLiability
40000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57323000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53306000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57323000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53306000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57300000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4000000.0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22555000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2023 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
201000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22756000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21399000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
135000
CY2023 cycc Undistributed Net Income Loss Available To Common Stockholders Diluted
UndistributedNetIncomeLossAvailableToCommonStockholdersDiluted
-22756000
CY2022 cycc Undistributed Net Income Loss Available To Common Stockholders Diluted
UndistributedNetIncomeLossAvailableToCommonStockholdersDiluted
-21534000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
852957
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
411869
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
420000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22555000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-21198000
CY2023Q4 us-gaap Assets
Assets
8805000
CY2022Q4 us-gaap Assets
Assets
28050000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2024Q1 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2024-01-12

Files In Submission

Name View Source Status
0001558370-24-003713-index-headers.html Edgar Link pending
0001558370-24-003713-index.html Edgar Link pending
0001558370-24-003713.txt Edgar Link pending
0001558370-24-003713-xbrl.zip Edgar Link pending
cycc-20231231.xsd Edgar Link pending
cycc-20231231x10k.htm Edgar Link pending
cycc-20231231x10k002.jpg Edgar Link pending
cycc-20231231x10k003.jpg Edgar Link pending
cycc-20231231xex10d13.htm Edgar Link pending
cycc-20231231xex10d13001.jpg Edgar Link pending
cycc-20231231xex10d13002.jpg Edgar Link pending
cycc-20231231xex23d1.htm Edgar Link pending
cycc-20231231xex31d1.htm Edgar Link pending
cycc-20231231xex31d2.htm Edgar Link pending
cycc-20231231xex32d1.htm Edgar Link pending
cycc-20231231xex32d2.htm Edgar Link pending
cycc-20231231xex4d12.htm Edgar Link pending
cycc-20231231xex97d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
cycc-20231231x10k_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cycc-20231231_cal.xml Edgar Link unprocessable
cycc-20231231_def.xml Edgar Link unprocessable
cycc-20231231_lab.xml Edgar Link unprocessable
cycc-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable